基于微小残留病不可测定义的标准风险儿童急性淋巴细胞白血病中减强度延迟强化:国际随机试验(AIEOP-BFM ALL 2000)结果
该国际随机试验纳入1164例标准风险儿童急性淋巴细胞白血病患者,随机接受减强度延迟强化(P-III)或标准延迟强化(P-II)。P-III组8年无病生存率为89.2±1.3%,低于P-II组的92.3±1.2%(P=0.04),主要因复发率增加,减强度未达非劣效。
要点
- 标准风险定义为无高危细胞遗传学且第33天和第78天微小残留病不可测。
- P-III组地塞米松累积剂量减少30%,长春新碱、多柔比星和环磷酰胺减少50%,疗程从49天缩短至29天。
- P-III组8年无病生存率89.2±1.3% vs P-II组92.3±1.2%(P=0.04),减强度未成功。
核心结论
- 尽管本试验的标准风险定义识别出预后极好的患者,但化疗减强度未成功,主要因复发率增加。
- 数据提示在特定亚组中治疗减强度可行,突显了按治疗反应筛选队列的生物学异质性。
研究设计与样本
- 国际随机试验AIEOP-BFM ALL 2000,2000年7月至2006年7月纳入1164例1至17岁标准风险急性淋巴细胞白血病患者。
- 标准风险定义为无高危细胞遗传学且第33天和第78天微小残留病不可测。
- 患者随机分配至实验性减强度延迟强化(方案III;P-III)或标准延迟强化(方案II;P-II),分析按实际接受治疗进行。
主要发现
- P-III组和P-II组8年无病生存率(±SE)分别为89.2±1.3%和92.3±1.2%(P=0.04)。
- P-III组和P-II组累积复发率分别为8.7±1.2%和6.4±1.1%(P=0.09)。
- P-III组和P-II组总生存率分别为96.1±0.8%和98.0±0.6%(P=0.06)。
- ETV6-RUNX1阳性ALL患者和1至6岁患者在两组中表现同样良好。
- P-III组和P-II组8年第二恶性肿瘤累积发生率分别为1.3±0.5%和0.6±0.4%(P=0.37)。
关键数值与推荐
- P-III组地塞米松累积剂量减少30%,长春新碱、多柔比星和环磷酰胺减少50%,治疗时长从49天缩短至29天。
- 缓解期间死亡发生率两组相当,表明毒性等效。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Delayed intensification (DI) is an integral part of treatment of childhood acute lymphoblastic leukemia (ALL), but it is associated with relevant toxicity. Therefore, standard-risk patients of trial AIEOP-BFM ALL 2000 (Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With ALL) were investigated with the specific aim to reduce treatment intensity. Patients and Methods Between July 2000 and July 2006, 1,164 patients (1 to 17 years of age) with standard-risk ALL (defined as the absence of high-risk cytogenetics and undetectable minimal residual disease on days 33 and 78) were randomly assigned to either experimental reduced-intensity DI (protocol III; P-III) or standard DI (protocol II; P-II). Cumulative drug doses of P-III were reduced by 30% for dexamethasone and 50% for vincristine, doxorubicin, and cyclophosphamide, which shortened the treatment duration from 49 to 29 days. The study aimed at noninferiority of reduced-intensity P-III; analyses were performed according to treatment given. Results For P-III and P-II, respectively, the 8-year rate of disease-free survival (± SE) was 89.2 ± 1.3% and 92.3 ± 1.2% ( P = .04); cumulative incidence of relapse, 8.7 ± 1.2% and 6.4 ± 1.1% ( P = .09); and overall survival, 96.1 ± 0.8% and 98.0 ± 0.6% ( P = .06). Patients with ETV6-RUNX1-positive ALL and patients 1 to 6 years of age performed equally well in both arms. The incidence of death during remission was comparable, which indicates equivalent toxicity. The 8-year cumulative incidence rate of secondary malignancies was 1.3 ± 0.5% and 0.6 ± 0.4% for P-III and P-II, respectively ( P = .37). Conclusion Although the criteria used for the standard-risk definition in this trial identified patients with exceptionally good prognosis, reduction of chemotherapy was not successful mainly because of an increased rate of relapse. The data suggest that treatment reduction is feasible in specific subgroups, which underlines the biologic heterogeneity of this cohort selected according to treatment response.
引用
- Schrappe M, Bleckmann K, Zimmermann M, et al. Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000). J Clin Oncol. 2017. PMID: 29148893. doi:10.1200/JCO.2017.74.4946
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。